Followers | 240 |
Posts | 12050 |
Boards Moderated | 1 |
Alias Born | 04/05/2009 |
Tuesday, July 11, 2023 7:23:27 PM
Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty
DALLAS, July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) (the "Company") to make available all books and records surrounding the proposed acquisition of the Company in order to investigate whether any board members breached their fiduciary duties in connection with the proposed acquisition. NexPoint Event Driven Fund is advised by NexPoint Asset Management, L.P. and together with other stockholders (collectively, "NexPoint"), are members of a group who beneficially own approximately 11.7% of the Company's outstanding common stock.
Link to letter:
https://www.nexpointassetmgmt.com/wp-content/uploads/2023/07/2023.07.11-PRTK-220-Demand.pdf
About NexPoint Event Driven Fund
NexPoint Event Driven Fund is an open-end mutual fund advised by NexPoint Asset Management, L.P. The fund invests in event catalysts including mergers, acquisitions, tender offers, restructuring, spin-offs, refinancings, recapitalizations or economic events that can impact specific industries.
About NexPoint Asset Management, L.P.
NexPoint Asset Management, L.P. is an SEC-registered investment adviser. NexPoint Asset Management, L.P. is the adviser to a suite of registered funds, including open-end mutual funds, closed-end funds, and an exchange-traded fund. The funds draw on NexPoint's investment capabilities, covering a range of asset classes and strategies. For more information visit www.nexpointassetmgmt.com/.
https://www.prnewswire.com/news-releases/nexpoint-sends-demand-letter-for-books-and-records-to-paratek-pharmaceuticals-in-connection-with-proposed-acquisition-by-gurnet-point-capital-301874809.html
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, Founder and CEO of Harwood International
Recent PRTK News
- Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023 • GlobeNewswire Inc. • 10/05/2023 12:00:00 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 10/02/2023 11:33:56 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/26/2023 04:15:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:24:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:24:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:23:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:21:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:21:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:18:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:17:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:13:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2023 05:12:37 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 09/21/2023 02:59:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/21/2023 02:42:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/21/2023 02:39:56 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM